Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Over 348 Drugs In Proposed Pricing Policy, India Aims To Balance Industry Growth With Affordable Drugs

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - After lying in hibernation for several years, policy proposals for tighter government control on pricing of the most used medicines in India is back in the headlines as the Department of Pharmaceuticals last week posted a comprehensive draft pricing policy and called for feedback from stakeholders before Nov. 30

You may also be interested in...



India’s Price Controls To Expand To All Essential Drugs; Impact On MNCs More Severe Than Indian Firms

Long winded discussions culminated in a proposed policy framework that may impact margins of larger brands, but the industry is not yet complaining.

India May Bring 348 Drugs Under Price Control But Combinations Likely Spared

In the final stages of readying a policy framework, India may go soft on price controls

Indian Industry Lobbies Press Hard For Market-Linked Pricing Policy Framework

Industry lobbies seek to demolish several myths to avoid a policy that may potentially harm the industry and does not favour consumers either.

Related Content

UsernamePublicRestriction

Register

SC076597

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel